(Q38060236)

28 August 2017

title

Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication (English)

1 reference

28 August 2017

2

Mark A Wainberg

1 reference

28 August 2017

author name string

Gerasimos J Zaharatos

series ordinal

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

17 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

45

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

236-241

1 reference

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.732704

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.732704

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.732704

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.732704

Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.732704

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.732704

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.732704

High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.732704

Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.732704

Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.732704

Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890.2012.732704

10.3109/07853890.2012.732704

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference